DHX33

Across TCGA pan-cancer cohorts, DHX33 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DHX33 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher DHX33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DHX33 expression acts as an unfavorable survival marker.

UCEC, COAD, and BLCA are the cancer types where DHX33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	6	view →
BLCA	OS	Median	IV	0.141	0.573	.034	3	view →
SKCM	OS	Median	III,IV	0.217	0.702	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DHX33–UCEC (OS)

Open the UCEC breakdown →